文献速递心境障碍会诊联络精神医学

精神疾病免疫调节药物临床试验的经验教训

Lessons From Clinical Trials of Immunomodulatory Drugs in Psychiatric Disorders.
PubMed 文献 · Biol Psychiatry · 2025-11-21

免疫失调参与精神疾病病理生理,外周炎症标志物与症状严重度、治疗难治性和神经环路功能障碍相关。免疫调节药物临床试验结果不一,如英夫利西单抗仅在外周炎症升高亚组中改善抑郁。经验教训包括需更大规模试验、生物标志物驱动选择及长期监测。

要点

  • 免疫调节药物在精神疾病中整体结果不一,英夫利西单抗仅在外周炎症升高亚组改善抑郁。
  • 多数试验样本小、未采用生物标志物富集,部分单克隆抗体研究已开始用炎症标志物指导分组。
  • 结局量表偏宽泛,未聚焦快感缺失等神经免疫相关表型,且试验周期短。

核心结论

  • 免疫调节药物在精神疾病中有潜力,但需更大规模、生物标志物驱动和长期监测的试验。

研究设计与样本

  • 本文为临床试验经验总结,涉及抗细胞因子治疗(单克隆抗体)、非甾体抗炎药和米诺环素等免疫调节药物的多项试验。

主要发现

  • 英夫利西单抗在外周炎症升高的亚组中改善抑郁,但整体结果不一。
  • 多数免疫调节试验样本小且未采用生物标志物富集,部分单克隆抗体研究已开始用炎症标志物指导亚组分析或入组。
  • 许多试验结局采用宽泛症状量表,未聚焦快感缺失等神经免疫相关精神表型。
  • 精神疾病试验评估短期效应,限制了对长期疗效、安全性和持续获益的了解。
  • 缺乏大型、多中心、充分把握度的研究,限制了普遍性。

临床怎么用

  • 临床可关注外周炎症标志物以识别可能从免疫调节治疗中获益的亚组。
  • 未来研究应聚焦神经免疫相关表型如快感缺失,并延长随访评估长期效益。

局限性

  • 多数试验样本小、未采用生物标志物富集,结局量表宽泛且试验周期短。
  • 缺乏大型多中心充分把握度研究,普遍性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune dysregulation has been implicated in the pathophysiology of psychiatric disorders, with peripheral inflammatory markers correlating with symptom severity, treatment refractoriness, and neural circuit dysfunction. This has led to growing interest in immunomodulatory drugs as potential treatments. Several clinical trials have explored the efficacy of anticytokine treatments (monoclonal antibodies [mAbs]), nonsteroidal anti-inflammatory drugs, and minocycline, among other agents. While there have been some promising results, such as improvement in depression with infliximab among subgroups with peripherally elevated inflammation, overall results have been mixed. Several key lessons have emerged from these studies that can guide future research and clinical care. While most immunomodulatory trials were small and did not utilize biomarker-based enrichment, some recent studies of mAbs have started to use inflammatory markers to guide subgroup analyses and/or enrollment. Outcome measures in many trials relied on broad symptom scales that did not focus on neuroimmune-related psychiatric phenotypes, such as anhedonia. While immunomodulatory drugs for most medical conditions are used as long-term treatments, the trials in psychiatric disorders assessed their effects over short durations, limiting insights into their long-term efficacy, safety, and potential for sustained psychiatric benefits. Absence of large, multicenter, well-powered studies limits the generalizability. Translational research on neuroimmune interactions is needed to refine therapeutic targets and optimize study designs. These lessons highlight the potential of immunomodulatory drugs in psychiatric disorders while emphasizing the need for larger, well-powered trials; biomarker-driven treatment selection; and long-term monitoring. With a targeted approach, immunomodulatory drugs represent an important step toward precision medicine in psychiatry.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Pak T, Haque N, Jha MK, et al. Lessons From Clinical Trials of Immunomodulatory Drugs in Psychiatric Disorders. Biol Psychiatry. 2025. PMID: 41275953. doi:10.1016/j.biopsych.2025.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。